Company news
Corvus Pharmaceuticals, Inc. news in 2021
Corvus Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2021
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
October 31, 2021
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
October 26, 2021
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
September 21, 2021
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
September 6, 2021
Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
August 15, 2021
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 1, 2021
Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
July 14, 2021
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
May 4, 2021
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
April 28, 2021
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 24, 2021
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
February 16, 2021
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
February 11, 2021
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 10, 2021
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
February 3, 2021